[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352804-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352804-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","vaccine-strategies-for-cancer-prevention-in-lynch-syndrome-the-potential-of-dendritic-cell-based-therapy","Vaccine strategies for cancer prevention in Lynch syndrome: the potential of dendritic cell-based therapy","","Cancer vaccines offer a promising strategy for cancer prevention, particularly in hereditary cancer syndromes such as Lynch syndrome (LS). LS is characterized by a high lifetime risk of developing malignancies caused by DNA mismatch repair defects, which lead to shared tumour-specific neoantigens created from frameshift insertion/deletions in microsatellite loci. These neoantigens appear in precancerous lesions, supporting immune-interception prevention approaches. The review surveys key antigens, delivery platforms, evaluates limited clinical outcomes, and highlights future directions, with emphasis on dendritic cell vaccination therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/vaccine-strategies-for-cancer-prevention-in-lynch-syndrome-the-potential-of-dendritic-cell-based-therapy/352804/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/vaccine-strategies-for-cancer-prevention-in-lynch-syndrome-the-potential-of-dendritic-cell-based-therapy/352804.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes Lynch syndrome suitable for preventive cancer vaccination?","Question",{"text":63,"@type":64},"LS involves DNA mismatch repair defects that generate shared tumour-specific neoantigens from microsatellite frameshift indels. These neoantigens are present in precancerous lesions, enabling immune interception before overt cancer develops.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are dendritic cell-based therapies positioned in the review?",{"text":68,"@type":64},"The review emphasizes the promising potential of dendritic cell vaccination therapy as a future approach for preventive cancer immunotherapy in LS.",{"name":70,"@type":61,"acceptedAnswer":71},"Why do therapeutic cancer vaccines often show limited clinical impact?",{"text":72,"@type":64},"Therapeutic vaccines are typically administered after disease is already advanced. Preventive vaccination strategies aim to overcome this by vaccinating before tumour onset or during early pre-malignant stages.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352804,1790442588,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Familial Cancer (2026) 25:41  \n[https://doi.org/10.1007/s10689-026-00559-y](https://doi.org/10.1007/s10689-026-00559-y)  \nREVIEW  \nVaccine strategies for cancer prevention in Lynch syndrome: the potential of dendritic cell-based therapy  \nRomy N. Kuipers1,3 · Mark A. J. Gorris1 · Cristina Bayó4 · Tom Hofland1 · Daniel Benítez Ribas4,6 ·  \nGeorgina Flórez Grau4 · Nicoline Hoogerbrugge2 · Joaquin Castillo4,5 · Francesc Balaguer4,5 · Tanya M. Bisseling3 · Gerty Schreibelt1 · I. Jolanda M. de Vries1  \nReceived: 28 January 2026 / Accepted: 11 April 2026 © The Author(s) 2026  \nAbstract  \nCancer vaccines offer a promising strategy for cancer prevention, particularly in hereditary cancer syndromes such as Lynch syndrome (LS) . LS is characterized by a high lifetime risk of developing various malignancies due to defects in DNA mismatch repair, leading to an accumulation of mutations, particularly frameshift insertion/deletions (indels) within microsatellite loci. These indels create shared tumour-specific neoantigens, which are unique to LS and can be recognized by the immune system and trigger cancer cell killing. Importantly, these neoantigens are also present in precancerous lesions, making LS an ideal target for immune-interception strategies aimed at prevention. Over the years, a variety of vaccine designs targeting different antigens along with a range of delivery platforms have been explored for different types of tumours, each with its own advantages and limitations. In this review, we provide an overview of the key antigensand delivery platforms used in cancer preventive vaccine development for LS, evaluate their limited clinical outcomes to date, and explore the future directions of preventive vaccine immunotherapy. A particular focus is placed on the promising potential of dendritic cell vaccination therapy as a future approach in this field.  \nKeywords Prevention · Cancer · Vaccines · Lynch syndrome · Hereditary cancer · Dendritic cells  \n􀀍 I. Jolanda M. de Vries [Jolanda.devries@radboudumc.nl](Jolanda.devries@radboudumc.nl)  \n1 Department of Medical BioSciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands  \n2 Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands  \n3 Department of Gastroenterology and Hepatology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands  \n4 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain  \n5 Department of Gastroenterology, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Facultat de Medicina i Ciències de la Salud, Hospital Clínic Barcelona, Universitat de Barcelona (UB), Barcelona, Spain  \n6 Department of Immunology, Hospital Clinic Barcelona, Barcelona, Spain  \n1. Introduction  \nImmunotherapy is an active field of research in cancer treatment and prevention [1] . Advances in our understanding of the tumour microenvironment have highlighted the impact of immune-suppressive pathways in cancer progression. This knowledge led to the development of therapies aimed at overcoming these inhibitory signals, with the exceptional successful development of immune checkpoint inhibitors targeting CTLA4 or PD1/PDL1 [2] . Such therapies have demonstrated sustained disease regression in subsets of patients, although not all benefit, and immune-related adverse events remain a challenge [3] . Building on these insights, combinatorial strategies that pair checkpoint inhibition with cancer vaccines have begun to show enhanced efficacy in preclinical and clinical settings [4, 5] . Nevertheless, the overall clinical impact of therapeutic vaccines remains low [6], in part because they are typically administered once disease is already advanced. Preventive vaccination strategies offer a way to circumvent this limitation. Administering vaccines prior to tumour onset, or during  \nearly pre-malignant stages, enables the im","cbCaifB9UkUqlsZb","https://ap.wps.com/l/cbCaifB9UkUqlsZb","pdf",1013120,15,"English","# Abstract\n# 1. Introduction\n## Immunotherapy advances and preventive vaccination rationale\n# Lynch syndrome and opportunities for vaccine development","[{\"question\":\"What makes Lynch syndrome suitable for preventive cancer vaccination?\",\"answer\":\"LS involves DNA mismatch repair defects that generate shared tumour-specific neoantigens from microsatellite frameshift indels. These neoantigens are present in precancerous lesions, enabling immune interception before overt cancer develops.\"},{\"question\":\"How are dendritic cell-based therapies positioned in the review?\",\"answer\":\"The review emphasizes the promising potential of dendritic cell vaccination therapy as a future approach for preventive cancer immunotherapy in LS.\"},{\"question\":\"Why do therapeutic cancer vaccines often show limited clinical impact?\",\"answer\":\"Therapeutic vaccines are typically administered after disease is already advanced. Preventive vaccination strategies aim to overcome this by vaccinating before tumour onset or during early pre-malignant stages.\"}]","Vaccine strategies for cancer prevention in Lynch syndrome: the potential of dendritic cell-based therapy | PDF",1790101438,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e95fdeb444d214a33c019cebdd029c6b.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2e122abc7095a73bcc467d353cd1aef.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71fd0799ae5d7b32d9ec597aacd73b50.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cad29d53dc9d0ed7c2d00cdd157d35c.webp",980,1301]